Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Trial Details

NCT ID
NCT06915025
Phase
PHASE3
Sponsor
Imunon
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
  • Paclitaxel
  • Carboplatin
  • Olaparib
  • Niraparib
Locations (sample)
  • Orlando, Florida, United States|28.53834,-81.37924
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Portland, Oregon, United States|45.52345,-122.67621
  • Sioux Falls, South Dakota, United States|43.54369,-96.72796
  • Chattanooga, Tennessee, United States|35.04563,-85.30968

Key Eligibility Criteria

  • Participants must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written …
  • Participants with a histologically confirmed diagnosis of high-grade non-mucinous epithelial ovarian (serous, endometrioid, carcinosarcoma, mixed e…
  • Participants eligible to receive neoadjuvant chemotherapy.
  • Participants will provide a tumor tissue sample at pre-screening or screening, via laparoscopy or image guided core biopsy for determination of con…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →